• Corpus ID: 36547150

Drug-induced weight gain: Rethinking our choices.

  title={Drug-induced weight gain: Rethinking our choices.},
  author={Katherine H. Saunders and Leon I. Igel and Alpana P. Shukla and Louis J Aronne},
  journal={The Journal of family practice},
  volume={65 11},
Weight gain secondary to medications is a potentially modifiable risk. Here's how to optimize drug choices for patients with several common conditions. 

Tables from this paper

Effect of Obesogenic Medications on Weight-Loss Outcomes in a Behavioral Weight-Management Program

This study aimed to evaluate a possible association between the use of obesogenic medications and inadequate weight loss in a behavioral weight‐management program.

Helping your obese patient achieve a healthier weight.

These tips will help identify underlying causes of obesity, address comorbid conditions, and provide patients with the tools they need to successfully lose weight.

Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey

This study aimed to evaluate trends in the use of obesogenic medications among adults and found no change in the number of prescriptions given for these medications or in the types of medications prescribed.

Iatrogenic Obesity.

These are the medications known to cause weight gain that have been identified as a contributing factor to a patient's obesity.

Practical Use of Pharmacotherapy for Obesity.

Medications that can lead to weight gain and potential alternatives, currently approved anti-obesity medications and best practices to individualize the selection process, and the use of testosterone in men with hypogonadism and obesity are reviewed.

Selective Serotonin Reuptake Inhibitors (SSRIs) and Weight Gain

  • L. Igel
  • Medicine
    Obesity Management
  • 2018
A 22-year-old female college student presents for a new patient visit, reports being diagnosed with depression, and feels that the paroxetine has improved her mood, however, she does note that since initiating the medication, she has gained 11 lb and has also experienced sexual side effects, including decreased libido.

Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease

Medical management for weight loss in NAFLD requires fibrosis staging and developing a patient-centered approach to assessment of patient weight and behavioral change goals, which requires a multimodal approach.

Current concepts in management of weight regain following bariatric surgery

Data is critically reviewed from retrospective and prospective studies pertaining to prevalence and predictors of weight regain following bariatric surgery, as well as the utility of behavioral and pharmacotherapeutic interventions to address post-surgical weight regain.

Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction

There is a vital need for expanded insurance coverage to help foster a weight-centric approach to T2DM management, which includes broader coverage of anti-diabetic medications with evidence of cardiovascular risk reduction and mortality benefit.



Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity

Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety, and should be considered for a treatment indication in patients with these conditions.

Bupropion for weight reduction

The present drug profile provides a review of the pharmacology of bupropion, clinical evidence of efficacy with regard to weight reduction, tolerability and risks, and the current and future role of this drug in the management of obesity.

Body weight changes with beta-blocker use: results from GEMINI.

Metoprolol tartrate was associated with increased weight gain compared to carvedilol; weight gain was most pronounced in subjects with hypertension and diabetes who were not taking insulin therapy.

Long-Term Weight Change after Initiating Second-Generation Antidepressants

Antidepressant drug therapy is significantly associated with long-term weight change at two years and may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications.

Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review.

The main objective of the majority of studies was to compare the efficacy and safety of drug therapy, with weight change recorded under safety outcomes; weight change was a primary outcome measure in only six studies.

Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.

A regression analysis suggested that beta-blockers were associated with an initial weight gain during the first few months, but after that, no further weight gain compared with controls was apparent and the first-line use of beta- blockers in obese hypertensive patients should be reviewed.

Effects of metformin on weight loss: potential mechanisms

  • S. MalinS. Kashyap
  • Medicine, Biology
    Current opinion in endocrinology, diabetes, and obesity
  • 2014
The potential mechanisms by which metformin decreases appetite and opposes unfavorable fat storage in peripheral tissues are discussed, which will likely lead to optimal co-prescription of lifestyle modification with pharmacology for the treatment of obesity independent of diabetes.

Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity

Future directions in the pharmacologic management of obesity are presented along with new diabetes medications that promote weight loss and reduce cardiovascular mortality and highlights important findings from clinical trials.

Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study

This study compared the efficacy and tolerability of adding sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, and an up to 20% increase in insulin dose in patients with uncontrolled type 2 diabetes on insulin therapy.

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

When added to maximal metformin therapy, all noninsulin antidiabetic drugs were associated with similar HbA(1c) reductions but differed in their associations with weight gain and risk of hypoglycemia.